Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast CancerGlobeNewsWire • 04/09/20
Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q4 2019 - Earnings Call TranscriptSeeking Alpha • 02/25/20
Guardant Health (GH) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 02/19/20
Guardant Health (GH) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 02/13/20